12 drugs in PBS limbo pileup

Twelve drugs that secured a recommendation at the PBAC’s November 2025 meeting have since stalled in the PBS listing process with the submissions for reimbursement marked inactive.

The list includes big names such as Biogen’s Skyclarys – the first treatment for the rare genetic disease Freiedreich ataxia and Apellis’ Syfovre, which was the only TGA approved treatment for geographic atrophy up until recently when Astellas Pharma’s Izervay was approved.

Submissions are considered inactive when a company has not advised whether they intend to proceed or not within 60 days of receiving the ratified PBAC minutes and often flags issues on conditions of the recommendation, such as pricing.